Provider of prescription medication for phenylketonuria (PKU)
Request Access

About Kuvan

Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.

  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Kuvan

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Kuvan

Kuvan has secured backing from 1 investor. Prominent investors backing the company include BioMarin Pharmaceutical. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Investor Description Founded Year Domain Location
Therapeutics for rare genetic diseases are developed by BioMarin Pharmaceutical.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Kuvan

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Kuvan

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Kuvan Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Kuvan

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Kuvan

Frequently Asked Questions about Kuvan

What does Kuvan do?

Provider of prescription medication for phenylketonuria (PKU). This medication is used to lower blood Phe levels in adults and children over one month of age with a specific type of PKU, in conjunction with a Phe-restricted diet. The medication offers various dosage forms and is supported by resources including clinical coordinators and educational materials. It addresses the management of PKU through a combination of pharmaceutical intervention and dietary control. The company also provides a trial program for eligible patients. Important safety information and potential side effects are clearly communicated.

Who are Kuvan's investors?

Kuvan has 1 investor. Key investors include BioMarin Pharmaceutical.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available